Cargando…
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously e...
Autores principales: | Lima, Thiago S., Souza, Luciano O., Iglesias-Gato, Diego, Elversang, Johanna, Jørgensen, Flemming Steen, Kallunki, Tuula, Røder, Martin A., Brasso, Klaus, Moreira, José M.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203833/ https://www.ncbi.nlm.nih.gov/pubmed/35721223 http://dx.doi.org/10.3389/fphar.2022.869461 |
Ejemplares similares
-
Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance
por: Lima, Thiago S., et al.
Publicado: (2021) -
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
por: Kroon, Jan, et al.
Publicado: (2016) -
Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021) -
Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer
por: Zhou, Hai-Hong, et al.
Publicado: (2019) -
Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer
por: Zhang, Die, et al.
Publicado: (2023)